ERS Webinar

View all ERS Webinar

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

Chair: Andrew Bush Speakers: Kian Fan Chung, Andrew Bush, Patient: Theo Shilpzand

Severe asthma accounts for a disproportionate amount of morbidity, mortality and consumption of health care costs. There are increasing numbers of expensive monoclonals for severe asthma which are FDA- and EMA- approved, but all are directed against Type 2 (T2) inflammation. The options for non-Type 2 (non-T2) asthma are much more limited. This webinar will provide an overview of the new ERS/ATS guidelines on definition, evaluation and treatment of severe asthma and how clinicians can apply the guidelines in practice.

Educational aims

  • To enable the participant to understand the indications and contraindications to the use of monoclonals targeting the T2 pathway
  • To understand the role of biomarkers (blood eosinophil count, exhaled nitric oxide, serum periostin) in predicting the response to currently-available biologicals
  • To consider the roles of azithromycin and tiotropium in severe asthma, in particular in non-T2 disease
  • To realise the gaps in present knowledge, and in particular the need to do trials in children and adolescents, the forgotten population


Lectures and question times, including the patient experience.


  • The patient experience – living with severe asthma, the difference monoclonals can make
  • Those current anti-T2 biologicals which are FDA- and EMA-approved and indications including biomarker-driven therapy
  • Non-T2 asthma and the therapeutic options
  • Paediatric aspects of severe asthma – the same or different to adults, and how this may affect response to treatment

Learning outcomes

Following this course, participants will be able to apply the new ERS/ATS guidelines for severe asthma in clinical practice including: choice of appropriate biologicals for patients with severe asthma, including using biomarkers to plan therapy; understanding of the options available for non-T2 asthma, especially azithromycin; and understanding the need for studies in children.

What is a webinar?

The webinar closely simulates a lecture-based teaching experience. The speaker can interact with the audience, just as in a classroom setting.

This webinar comprises 45-minute lecture followed by a 15-minute question-and-answer sessions. During the webinar you will be asked to share your opinion on issues related to the topic using interactive polls. Your answers are not evaluated but participation is mandatory to obtain the CME credits.

All participants will be able to hear the lecturer and see the slides throughout the presentation. As a participant you will be able to pose questions or discuss ideas with the other participants via the text chat facility and the speaker will respond to the questions via the microphone.

Log in guidelines

To attend the webinar you will need to log in to an Adobe Connect platform. We will send you related login information one week before the webinar is due to commence.

In order to benefit from this live experience we advise that you ensure that your equipment is compatible with the technical specifications listed here:

It is also recommended that you perform a system test.

  • Please log in to the webinar 20 minutes before it is scheduled to commence. If you have any technical difficulties whilst trying to log in or during the session please contact
  • Check Central European Time.
  • To achieve the best quality, we recommend to stop all other programmes and to avoid downloading anything from the internet during your connection to the lecture.
  • Please also ensure that your audio settings are not set to mute and adjust the volume to a comfortable level.

Target Audience

  • Adult Pulmonologist/Clinician
  • General Practitioner
  • Other
  • Patient
  • Physician in Pulmonary Training
  • Sales, Marketing

Diseases / Methods

Airway diseases
General respiratory patient care
Public health